867 related articles for article (PubMed ID: 23022475)
1. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
2. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
5. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
6. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
8. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
9. Treating cancer with genetically engineered T cells.
Park TS; Rosenberg SA; Morgan RA
Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
[TBL] [Abstract][Full Text] [Related]
10. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
[No Abstract] [Full Text] [Related]
11. Adoptive T cell therapy: points to consider.
Yee C
Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
[TBL] [Abstract][Full Text] [Related]
12. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
Sukari A; Abdallah N; Nagasaka M
Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific allogeneic cells for cancer therapy.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2011 Dec; 11(12):1551-4. PubMed ID: 21995504
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
18. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
19. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI
Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957
[TBL] [Abstract][Full Text] [Related]
20. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]